TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8635262

Group type: EXPERIMENTAL
Intervention: LDL-apheresis plus medication (simvastatin 40 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medication alone (simvastatin 40 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LDL-apheresis plus medication
Number of subjects: 42

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 42
Study: 2063706

Group type: EXPERIMENTAL
Intervention: Early triers (students who tried one or more cigarettes)
Number of subjects: 1663

Group type: COMPARATOR
Intervention: Never-triers (students who never tried a cigarette)
Number of subjects: 1663

Group type: EXPERIMENTAL
Intervention: Psychosocial characteristics
Number of subjects: 1663
Study: 31245901

Group type: EXPERIMENTAL
Intervention: NPWT with saline irrigation (NPWT-I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional NPWT device (NPWT-C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional NPWT device (NPWT-K)
Number of subjects: 90
Study: 30298422

Group type: EXPERIMENTAL
Intervention: Activity tracking wristband feedback
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 132
Study: 29237497

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) levels in serum and bronchoalveolar lavage fluid (BALF)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) levels in serum and BALF
Number of subjects: 86
Study: 26490099

Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Continuing smokers (control)
Number of subjects: 937
Study: 23335150

Group type: EXPERIMENTAL
Intervention: CONNECT with physician summary
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: CONNECT without physician summary
Number of subjects: 743

Group type: COMPARATOR
Intervention: Control
Number of subjects: 743
Study: 21556784

Group type: EXPERIMENTAL
Intervention: Telephonic quitline intervention (counseling and nicotine replacement therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based group counseling intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (quitline and group counseling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19382469

Group type: EXPERIMENTAL
Intervention: Integrative medical regimen (IMR) - Jiangya Capsule (JYC) and Nimodipine (ND)
Number of subjects: 135

Group type: COMPARATOR
Intervention: JYC plus ND simulator (Group B)
Number of subjects: 135

Group type: COMPARATOR
Intervention: ND plus JYC simulator (Group C)
Number of subjects: 135
Study: 17097698

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets (ITNs)
Number of subjects: 19679

Group type: COMPARATOR
Intervention: Interruption of ITN intervention
Number of subjects: 19679
Study: 14760542

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (n=80)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Autogenic training (n=71)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Standard rehabilitation programme (Control group, n=78)
Number of subjects: 229
Study: 12365016

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with mitomycin C (6 mg/m(2) i.v.) and 5‐fluorouracil (310 mg/m(2) i.v.) for 5 consecutive days during postoperative Weeks 1 and 3, followed by 5‐FU (100 mg/m(2) orally) daily from postoperative Week 5 until disease recurrence.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with mitomycin C and 5‐fluorouracil.
Number of subjects: 112
Study: 9658721

Group type: EXPERIMENTAL
Intervention: CD117 antigen expression (clone 95C3) determined by flow cytometry in AML patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CD117 antigen expression in M5 subtype
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Correlation analysis of CD117 with other antigens
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Surface expression of CD117 in ALL
Number of subjects: 135
Study: 7648285

Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg every 8 h for 3 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Didanosine (200 mg every 12 h for 3 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine coadministered for 3 days
Number of subjects: 6
Study: 2649867

Group type: EXPERIMENTAL
Intervention: Oxytetracycline, Doxycycline, Rifampin (oral monotherapy)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: TMP/SMX (oral monotherapy)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Rifampin plus Oxytetracycline (combined oral therapy)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Rifampin plus TMP/SMX (combined oral therapy)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Oxytetracycline plus TMP/SMX (combined oral therapy)
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Oral monotherapy combined with Streptomycin
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Oral monotherapy combined with Gentamicin
Number of subjects: 1100
Study: 322791

Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (untreated eye)
Number of subjects: 100
Study: 30596530

Group type: EXPERIMENTAL
Intervention: 3D-ARS training (30 minutes, thrice per week for 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional physical fitness program (thrice per week for 1 month)
Number of subjects: 36
Study: 27647603

Group type: EXPERIMENTAL
Intervention: Orthosis group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 24825404

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (220 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23369983

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) for 8 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study: 21377034

Group type: EXPERIMENTAL
Intervention: Peanut OIT (peanut flour)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18029344

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol (PRO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spinal anaesthesia (SA)
Number of subjects: 30
Study: 16756424

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Naltrexone (targeted fashion)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 15083598

Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein IIb/IIIa inhibitors
Number of subjects: 100
Study: 10998012

Group type: EXPERIMENTAL
Intervention: HLA‐DRB1*0701 allele
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: HLA‐DRB1*0701 allele and D14S50 allele 170
Number of subjects: 181

Group type: COMPARATOR
Intervention: D14S50 alleles alone
Number of subjects: 181
Study: 9498150

Group type: EXPERIMENTAL
Intervention: Transtrochanteric approach
Number of subjects: 264

Group type: COMPARATOR
Intervention: Liverpool approach
Number of subjects: 264

Group type: COMPARATOR
Intervention: Hardinge approach
Number of subjects: 264
Study: 7900936

Group type: EXPERIMENTAL
Intervention: Levothyroxine (100 micrograms)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Iodine (200 micrograms)
Number of subjects: 37
Study: 2877682

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tubocurarine 0.5 mg kg‐1
Number of subjects: 10
Study: 29590380

Group type: EXPERIMENTAL
Intervention: 10-item Moral Injury Symptom Scale - Military Version Short Form (MISS-M-SF)
Number of subjects: 427
Study: 27392430

Group type: EXPERIMENTAL
Intervention: Self‐monitoring and feedback; action planning; normative feedback; cognitive bias re‐training; identity change (delivered via the 'Drink Less' app)
Number of subjects: 0
Study: 25400004

Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (hospital-based rehabilitation)
Number of subjects: 120
Study: 23745947

Group type: EXPERIMENTAL
Intervention: Crushed morphine sulfate controlled-release (CR) tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crushed morphine sulfate and naltrexone hydrochloride extended-release capsules (MSN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20888274

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA, 980-nm)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Sapheno-femoral ligation and stripping (SFL/S)
Number of subjects: 121
Study: 19038705

Group type: EXPERIMENTAL
Intervention: Double-bundle technique with bioabsorbable screw fixation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-bundle technique with bioabsorbable screw fixation
Number of subjects: 60
Study: 16869455

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 815

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study: 14618043

Group type: EXPERIMENTAL
Intervention: 1.5 g/day MgSO(4) infusion in 100 mL 0.9 NaCl solution (25 mL/hr) for 4 days after surgery
Number of subjects: 148

Group type: COMPARATOR
Intervention: 100 mL 0.9 NaCl solution (25 mL/hr)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: MgSO(4) infusion
Number of subjects: 148
Study: 11051622

Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg bd for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pivmecillinam 200 mg bd for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norfloxacin 400 mg bd for 3 days
Number of subjects: 0
Study: 8873548

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 32
Study: 1559143

Group type: EXPERIMENTAL
Intervention: Primes presented to the left visual field for high schizotypes (males)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primes presented to the right visual field for high schizotypes (males)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primes presented to both visual fields for low schizotypes (males)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall performance for females
Number of subjects: 0
Study: 3160915

Group type: EXPERIMENTAL
Intervention: Ketanserin, 40 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 800 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ketoconazole, 400 mg
Number of subjects: 11
Study: 30872380

Group type: EXPERIMENTAL
Intervention: TAS-121
Number of subjects: 0
Study: 27823876

Group type: EXPERIMENTAL
Intervention: 0.2 mL intranasal midazolam
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 0.5 mL intranasal midazolam
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 1 mL intranasal midazolam
Number of subjects: 99
Study: 25946554

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every 2 weeks after a loading dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methotrexate (7.5-25 mg/wk)
Number of subjects: 30
Study: 23394621

Group type: EXPERIMENTAL
Intervention: Ceftizoxime administered pre-incision
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ceftizoxime administered post-clamping of the umbilical cord
Number of subjects: 180
Study: 21882789

Group type: EXPERIMENTAL
Intervention: Plate fixation of clavicle fractures
Number of subjects: 28
Study: 19814948

Group type: EXPERIMENTAL
Intervention: Increased-dose selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Continued SSRI plus placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Medication optimization with SSRI plus clonazepam
Number of subjects: 46
Study: 16713784

Group type: EXPERIMENTAL
Intervention: Bimanual laryngoscopy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Cricoid pressure
Number of subjects: 104

Group type: COMPARATOR
Intervention: BURP (Backward-Upward-Rightward Pressure)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No manipulation
Number of subjects: 104

Group type: COMPARATOR
Intervention: BURP
Number of subjects: 104
Study: 14989694

Group type: EXPERIMENTAL
Intervention: Radical reconstruction of the soft palate musculature
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preoperative gap size > 13 mm
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Severity of SMCP (total SMCP score of 0 to 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Less abnormal muscle anatomy
Number of subjects: 40
Study: 12123332

Group type: COMPARATOR
Intervention: Cisplatin-carboplatin-ifosfamide (CCI)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Cisplatin-carboplatin-gemcitabine (CCG)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Ifosfamide-gemcitabine (IG)
Number of subjects: 284
Study: 10806822

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 7973074

Group type: EXPERIMENTAL
Intervention: AFB (Augmented Feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMFB (Learning Model Feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMFB+AFB (Learning Model Feedback + Augmented Feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 3394901

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia via catheter with prilocaine combined with general anaesthesia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Modified neurolept analgesia (balanced)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Correction of SaO2 using an adjusted formula
Number of subjects: 22
Study: 31971296

Group type: EXPERIMENTAL
Intervention: Radiomic texture analysis on native T1-maps
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: DTE classifier
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Radiomic analysis of native T1-images
Number of subjects: 188
Study: 31621181

Group type: EXPERIMENTAL
Intervention: Diabetes Symptom Management Program (DSMP) with usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 28438471

Group type: EXPERIMENTAL
Intervention: Actovegin treatment
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study: 25523883

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg, twice daily for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 50
Study: 23819225

Group type: EXPERIMENTAL
Intervention: Floating acupuncture
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Local Chinese herbs fumigation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral administration of western medicine
Number of subjects: 90
Study: 21333021

Group type: EXPERIMENTAL
Intervention: FITNET (web-based cognitive behavioural therapy)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study: 19772178

Group type: EXPERIMENTAL
Intervention: Profile Soft-Seal Cuff (PSSC)
Number of subjects: 138

Group type: COMPARATOR
Intervention: ProSeal LMA (PLMA)
Number of subjects: 138
Study: 16442975

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15339759

Group type: EXPERIMENTAL
Intervention: Surgical treatment for stress urinary incontinence
Number of subjects: 20
Study: 11352372

Group type: EXPERIMENTAL
Intervention: Reading aloud with distorted feedback of their own voice
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reading aloud with distorted alien feedback
Number of subjects: 38
Study: 9053465

Group type: EXPERIMENTAL
Intervention: Low-dose filgrastim (50 microg/m2)
Number of subjects: 38
Study: 8299450

Group type: COMPARATOR
Intervention: Fasting glucose challenge test
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1-h postprandial study
Number of subjects: 22

Group type: COMPARATOR
Intervention: 2-h postprandial study
Number of subjects: 22
Study: 3585444

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: O + CAF
Number of subjects: 131
Study: 29681235

Group type: EXPERIMENTAL
Intervention: Melatonin niosomes (MN) gel, 2.5 mg, 5 mg, and 10 mg, topically applied
Number of subjects: 14

Group type: COMPARATOR
Intervention: Melatonin gel (control)
Number of subjects: 14
Study: 25651897

Group type: EXPERIMENTAL
Intervention: Wrestling skills training (experimental group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no wrestling skills training)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between experimental and control groups
Number of subjects: 28
Study: 26621513

Group type: EXPERIMENTAL
Intervention: Computerised cognitive behaviour therapy (cCBT)
Number of subjects: 36
Study: 24354476

Group type: EXPERIMENTAL
Intervention: Multijoint functional training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single joint training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of multijoint functional and single joint robotic training
Number of subjects: 20
Study: 20966360

Group type: EXPERIMENTAL
Intervention: ACT and mindfulness intervention (n = 49)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Waiting-list control group (n = 44)
Number of subjects: 93
Study: 18212332

Group type: EXPERIMENTAL
Intervention: Blocking penalization of successful women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive feedback about potential to succeed
Number of subjects: 0
Study: 17233364

Group type: EXPERIMENTAL
Intervention: AAI-guided endotracheal intubation at AAI value of 15
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: AAI-guided endotracheal intubation at AAI value of 20
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (experience-guided intubation)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: AAI-guided endotracheal intubation at AAI value of 30
Number of subjects: 104
Study: 14998221

Group type: EXPERIMENTAL
Intervention: Enfuvirtide plus an optimized background (OB) regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized Regimen Only (OB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Number of subjects: 0
Study: 11257563

Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG): 2 mg/kg BN 52021, administered intravenously 120 mg BN 52021 before reperfusion.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose group (HDG): 10 mg/kg BN 52021, administered intravenously 600 mg BN 52021 before reperfusion.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG): Placebo administered before reperfusion.
Number of subjects: 24
Study: 9374695

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 7506166

Group type: EXPERIMENTAL
Intervention: nimesulide 200 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: ketoprofen 150 mg/day
Number of subjects: 40
Study: 2872807

Group type: EXPERIMENTAL
Intervention: Terazosin plus diuretic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus diuretic
Number of subjects: 0
Study: 30951550

Group type: EXPERIMENTAL
Intervention: Irreversible neurotmesis group (sciatic nerves transected)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (sham operation)
Number of subjects: 24
Study: 27751628

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - received orientation to replace processed foods with phosphorus additives with foods without additives
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control Group (CG) - received only nutritional orientation before the study
Number of subjects: 134
Study: 26444980

Group type: EXPERIMENTAL
Intervention: Standard quit advice and medicinal nicotine (Condition A)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Quit or substitute advice and medicinal nicotine (Condition B)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Quit or substitute advice and medicinal nicotine and e‐cigarettes (Condition C)
Number of subjects: 1600
Study: 24086334

Group type: EXPERIMENTAL
Intervention: Azithromycin (30 mg/kg single dose)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 22185601

Group type: EXPERIMENTAL
Intervention: Vaccinated with heterologous vaccine (HE)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Vaccinated with homologous inactivated vaccine (HO)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-vaccinated (NV)
Number of subjects: 110
Study: 19214923

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 87
Study: 18337638

Group type: EXPERIMENTAL
Intervention: Caffeine (1.75 mg/kg) 3 times daily for 4 consecutive weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15050493

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fat-free meal (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Meals with saturated fat and monounsaturated fat
Number of subjects: 10
Study: 11686822

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMPs) combined with bovine porous bone mineral (BPBM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 24
Study: 9152821

Group type: EXPERIMENTAL
Intervention: Povidone iodine dry powder spray at dressing changes
Number of subjects: 130

Group type: COMPARATOR
Intervention: No povidone iodine spray (control group)
Number of subjects: 130
Study: 8253556

Group type: EXPERIMENTAL
Intervention: TANIS stage
Number of subjects: 86
Study: 3820066

Group type: EXPERIMENTAL
Intervention: Walking briskly for 10 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Candy bar (sugar snack)
Number of subjects: 18